CoChat

Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re‐expressing the epigenetically repressed tumor suppressor—estrogen receptor β

Sharma, Vikas, Verma, Vikas, Lal, Nand, Yadav, Santosh K., Sarkar, Saumya, Mandalapu, Dhanaraju, Porwal, Konica, Rawat, Tara, Maikhuri, J.P., Rajender, Singh, Sharma, V.L., Gupta, Gopal · 2016 · Molecular Carcinogenesis
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Estrogen Receptor‐β (ER‐β), a tumor‐suppressor in prostate cancer, is epigenetically repressed by hypermethylation of its promoter. DNA‐methyltransferases (DNMTs), which catalyze the transfer of methyl‐groups to CpG islands of gene promoters, are overactive in cancers and can be inhibited by DNMT‐inhibitors to re‐express the tumor suppressors. The FDA‐approved nucleoside DNMT‐inhibitors like 5‐Azacytidine and 5‐Aza‐deoxycytidine carry notable concerns due to their off‐target toxicity, therefore non‐nucleoside DNMT inhibitors are desirable for prolonged epigenetic therapy. Disulfiram (DSF), an antabuse drug, inhibits DNMT and prevents proliferation of cells in prostate and other cancers, plausibly through the re‐expression of tumor suppressors like ER‐β. To increase the DNMT‐inhibitory activity of DSF, its chemical scaffold was optimized and compound‐339 was discovered as a doubly potent DSF‐derivative with similar off‐target toxicity. It potently and selectively inhibited cell proliferation of prostate cancer (PC3/DU145) cells in comparison to normal (non‐cancer) cells by promoting cell‐cycle arrest and apoptosis, accompanied with inhibition of total DNMT activity, and re‐expression of ER‐β (mRNA/protein). Bisulfite‐sequencing of ER‐β promoter revealed that compound‐339 demethylated CpG sites more efficaciously than DSF, restoring near‐normal methylation status of ER‐β promoter. Compound‐339 docked on to the MTase domain of DNMT1 with half the energy of DSF. In xenograft mice‐model, the tumor volume regressed by 24% and 50% after treatment with DSF and compound‐339, respectively, with increase in ER‐β expression. Apparently both compounds inhibit prostate cancer cell proliferation by re‐expressing the epigenetically repressed tumor‐suppressor ER‐β through inhibition of DNMT activity. Compound‐339 presents a new lead for further study as an anti‐prostate cancer agent. © 2015 Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mc.22433

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 39

Metadata

Authors
Sharma, V., Verma, V., Lal, N., Yadav, S. K., Sarkar, S., Mandalapu, D., Porwal, K., Rawat, T., Maikhuri, J. P., Rajender, S., Sharma, V. L., & Gupta, G.
Venue
Molecular Carcinogenesis
Publisher
Wiley
Published
2015-11-24
Volume
55
Issue
11
Pages
1843-1857
ISSN
  • 0899-1987 (ISSN-L)
  • 1098-2744
OpenAlex
W2180153434
Cited by
39
References
2
FWCI
1.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re‐expressing the epigenetically repressed tumor suppressor—estrogen receptor β. https://app.cochat.ai/papers/10.1002/mc.22433
The paper
Sharma, V., Verma, V., Lal, N., Yadav, S. K., Sarkar, S., Mandalapu, D., Porwal, K., Rawat, T., Maikhuri, J. P., Rajender, S., Sharma, V. L., & Gupta, G. (2016). Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re‐expressing the epigenetically repressed tumor suppressor—estrogen receptor β. Molecular Carcinogenesis. https://doi.org/10.1002/mc.22433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.